# Hopo Therapeutics, Inc.

Canonical: https://abierto.us/vendors/hopo-therapeutics-inc-h5mwn5zbxq98

- UEI: H5MWN5ZBXQ98
- CAGE: 8L3L6
- Location: Berkeley, CA
- Awards in window: 1 (5 transactions), $14,209,253 obligated, September 27, 2024 to April 27, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $14,209,253

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $14,209,253

## Competition

- Full and Open Competition: 1 awards

## Solicitations won

- Development of the Actinide Decorporation Agent HOPO-101 for Broad Spectrum Heavy Metal Exposure (75A50124C00062), $226,309,811. https://abierto.us/opportunities/75a50124c00062

## Largest awards

- 75A50124C00062 (definitive contract): $14,209,253, Barda - Aspr / Daappo / Barda DCMA. Development of Hopo-101 as an MCM (Medical Countermeasure) Decorporation Agent for the Treatment of Individuals with Known or Suspected Internal Contamination with Radionuclides (The ?mcm Indication?) And/Or Toxic Heavy Metals of Interest for Commerc. https://www.usaspending.gov/award/CONT_AWD_75A50124C00062_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/hopo-therapeutics-inc-h5mwn5zbxq98.